Clinical trials: AD-MCI
Alzheimer's Disease, MCI Due to AD
Language, Speech and Motor Function in MCI Due to AD and Alzheimer's Disease
The goal of this observational cross-sectional study is to explore the characteristics of language, speech, and motor function in persons with Mild Cognitive Impairment due to Alzheimer's disease ("MCI due to AD") and persons…
- Conditions
- Alzheimer's Disease, MCI Due to AD, Dementia Alzheimers
- Trial name
- NCT06508268
- Testing
- GAITRite walkway system OR 4-meter walking speed test, Jamar hand dynamometer, Picture description task
- Where
- Netherlands
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Hanze University of Applied Sciences Groningen
Neurodegenerative Diseases
Pilot Study About Extra Virgin Olive Oil "Coratina" in Mild Cognitive Impairment and Alzheimer's Disease Patients
Alzheimer's Disease is a neurodegenerative disease age related caused by neurofibrillary tangles misfolding and Beta-amyloid protein accumulation.
- Trial name
- EVOCAD (NCT04229186)
- Testing
- EVOO-C, ROO
- Volunteers
- 24 people
- Sponsor
- University of Bari Aldo Moro
Mild Cognitive Impairment
Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI
To investigate whether [18F]NAV4694 positron emission tomography (PET) scan findings have the ability to distinguish subjects with mild cognitive impairment (MCI) who progress to Alzheimer's disease (AD) from those who do not.
- Trial name
- NAV4-04 (NCT01812213)
- Testing
- [18F]NAV4694
- Where
- 11 sites in United States
- Volunteers
- 76 people
- Sponsor
- Navidea Biopharmaceuticals
Mild Cognitive Impairment (MCI), Mild Alzheimer Disease
iTBS in MCI and Mild AD
This study aims to examine the effects of iTBS on cognitive function in individuals with MCI or mild AD, with a secondary objective of exploring prefrontal TBS mechanisms for cognitive function and the effect of iTBS on BDNF.
- Trial name
- NCT06670820
- Testing
- Active rTMS
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Defense Medical Center, Taiwan
Mild Cognitive Impairment, Alzheimer Disease
Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD
The purpose of this study is to evaluate the safety and tolerability of allopregnanolone, a naturally occurring brain steroid, in mild cognitive impairment and early Alzheimer's disease participants.
- Trial name
- Allo (NCT02221622)
- Testing
- Allopregnanolone injection (intravenous solution)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Southern California
Alzheimer's Disease
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
This study will assess the effects of VX-745 on markers of disease in the central nervous system of patients with MCI due to AD or with mild AD.
- Trial name
- NCT02423200
- Testing
- VX-745
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Mild Cognitive Impairment, Alzheimer Disease
Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure
The proposed project will assess long-term changes to health/lifestyle, advanced planning, and research engagement that Black and White patients with Amnestic Mild Cognitive Impairment (aMCI) make following disclosure of positron…
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Amnestic Mild Cognitive Disorder
- Trial name
- SHARED III (NCT05584241)
- Testing
- Diagnostic Disclosure Protocol, Biomarker Disclosure Protocol
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Michigan
Alzheimer s Disease
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study
- Trial name
- NCT07764146
- Testing
- VY1706 Low dose, VY1706 Mid dose, VY1706 High Dose
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Voyager Therapeutics
Mild Cognitive Impairment
Metformin in Amnestic Mild Cognitive Impairment
Hyperinsulinemia and type 2 diabetes (T2D) are important potential risk factors for cognitive decline and Alzheimer's disease (AD).
- Trial name
- MCI (NCT00620191)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Columbia University
Alzheimer´s Disease
Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with MCI or Alzheimer's Disease (AD).
- Trial name
- AD Biomarker (NCT07741526)
- Testing
- NPI-001
- Where
- 4 sites in Denmark, Iceland
- Volunteers
- 33 people
- Sponsor
- Arctic Therapeutics
Alzheimer Disease
A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers
This study will test two different doses of florbetapir F 18 to determine which dose is best to image amyloid plaques in the brains of Alzheimer's Disease (AD) patients using a positron emission tomography (PET) scanner.
- Trial name
- NCT01565330
- Testing
- florbetapir F 18
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Mild Cognitive Impairment
The Role of Ophthalmologic Tests and EEG Imaging in Alzheimer's Disease
Alzheimer's disease (AD) is a prevalent, long-term progressive degenerative disorder with great social impact. It is currently thought that, in addition to neurodegeneration, vascular changes also play a role in the…
- Trial name
- NCT04277767
- Testing
- observational
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Alzheimer's Disease (AD)
Cognitive Health in Ageing Register: Investigational and Observational Trial Studies in Dementia Research (CHARIOT): Prospective Readiness Cohort (PRO) Longitudinal Study
Alzheimer's disease is a degenerative condition affecting the brain and is the most frequent form of dementia in older adults. Dementia is currently a major healthcare issue in the UK, affecting approximately a million people.
- Trial name
- CPLS (NCT06953167)
- Where
- United Kingdom
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Dementia, Mild Cognitive Impairment (MCI)
Comprehensive Assessment of Neurodegeneration and Dementia
This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits.
- Conditions
- Dementia, Mild Cognitive Impairment (MCI), Subjective Cognitive Impairment, Parkinson's Disease (PD)
- Trial name
- COMPASS-ND (NCT03402919)
- Where
- 19 sites in Canada
- Volunteers
- 1,573 people, healthy volunteers welcome
- Sponsor
- McGill University
Mild Cognitive Impairment, Mild Alzheimer's Disease
A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.
A randomized-control, double-blind, multi-center, delayed-start, pilot trial evaluating the disease modifying effects of a 150mg once-a-day dose vs.
- Trial name
- NCT03752294
- Testing
- Dabigatran
- Sponsor
- University of Rhode Island
Alzheimer Disease, Cognitive Dysfunction
Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type
A Randomized Pivotal Study of RenewTM NCP-5 for the Treatment of Mild Cognitive Impairment due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type is a pivotal, single blind, parallel design, multi-site study intends…
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Mild Cognitive Impairment, Mild Dementia
- Trial name
- NCT03721705
- Testing
- Renew NCP-5
- Where
- 12 sites in United States, Ireland and 1 more
- Volunteers
- 190 people
- Sponsor
- Renew Research, LLC
Alzheimer Disease, Mild Cognitive Impairment
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
The purpose of this study is to learn about health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in the United States.
- Trial name
- GERAS-US (NCT02951598)
- Testing
- Florbetapir F 18 PET Scan
- Where
- 77 sites in United States
- Volunteers
- 1,400 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease, Mild Cognitive Impairment
A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
- Trial name
- NCT00702143
- Testing
- florbetapir F 18
- Where
- 15 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER)
This single-center prospective cohort study will enroll 750 participants (250 cognitively Normal (CN) individuals, 250 with mild cognitive impairment (MCI), and 250 with Alzheimer's disease (AD)).
- Trial name
- AD-MINER (NCT07089303)
- Where
- China
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
[18F]APN-1607 PET in Subjects With AD Compared to HC
The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MCI, subjects with AD dementia, and healthy subjects.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
- Trial name
- NCT05542953
- Testing
- [18F]APN-1607
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- APRINOIA Therapeutics